Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Updated results from a Phase II study of minimal residual disease-guided venetoclax + obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 3902.

https://doi.org/10.1182/blood-2025-3902

Published: 2025

Journal Articles

Molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation

Blood (2025) 146 (Supplement 1): 2102.

https://doi.org/10.1182/blood-2025-2102

Published: 2025

Journal Articles

A Phase II multicenter study of minimal residual disease-guided, time-limited acalabrutinib + obinutuzumab for the initial treatment of chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 5676.

https://doi.org/10.1182/blood-2025-5676

Published: 2025

Journal Articles

Pre-Clinical Evaluation of AZD5492, a Novel CD8-Guided T Cell Engager, for B-Non Hodgkin Lymphoma Indications

Blood (2024) 144 (Supplement 1): 959.

https://doi.org/10.1182/blood-2024-198745

Published: 2024

Journal Articles

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

John F. Seymour, John C. Byrd, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O’Brien, Jennifer R. Brown, Talha Munir, Anthony Mato, Stephan Stilgenbauer, Naghmana Bajwa, Paulo Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach

Blood (2023) 142 (8): 687–699.

https://doi.org/10.1182/blood.2022018818

Published: 2023

Includes: Supplemental data

Journal Articles

Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax in the Clinical Trial and Post-Marketing Settings

John F. Seymour, John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci, Matthew S. Davids, MD, Anthony Mato, MD, Jeff P Sharman, MD, Aimee Cyr, Cynthia Bartkus, German Pena, MD, Michelle Boyer, Simon Sharmokh, MPH, PharmD, Tanya S Rosenberg, MD, William G. Wierda, MD PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-134938

Published: 2020

Journal Articles

A Clinical Practice Comparison of Overall Survival, Time-to-Next-Treatment, and Time-to-Treatment-Discontinuation Among CLL/SLL Patients Receiving First-Line Ibrutinib with and without a Del(17p) Mutation

Anthony Mato, MD, Boxiong Tang, MD PhD, Soraya Azmi, MBBS,MPH, Keri Yang, PhD MPH, MS, Jennifer C Stern, PhD, Eric Hedrick, MD, Jane Huang, MD, Jeff P Sharman, MD

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-134119

Published: 2020

Journal Articles

COVID-19 Impact on Lymphoma Patients' Clinical Outcomes - an Observational Cohort Study

Andrew Ip, MDMSc, Anthony Mato, MD, Jordan Intrator, Nicholas P Howard, Alessandra Petrillo, MD, Rosalba Vicioso, BA, Rani Sebti, MD, Cristina Cicogna, MD, Gabriella Magarelli, ACNP-BC, Lori A. Leslie, MD, Andre H. Goy, MD, Tatyana A. Feldman, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141871

Published: 2020

Journal Articles

LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-134314

Published: 2020

Journal Articles

The Prosid Study: Evaluating Efficacy and Safety of Intravenous Immunoglobulin (IVIG) 10% in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia- Study Design

Oliver Cornely, MD, Anthony Mato, MD, Tadeusz Robak, MDPhD, Sibylle Mellinghoff, MD, Tatiana Lavrova, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-136898

Published: 2020

Journal Articles

Improving Physician-Patient Decision Making for Treatment of Chronic Lymphocytic Leukemia with BTK Inhibition

Tariqa A Ackbarali, PhDc), Matthew S. Davids, MD, Wendy Turell, Maria Arnone, Anthony Mato, MD, Brian Koffman, MDM, DCFP, DABFM, MSEd, Elizabeth A Del Nido, Kim Jacobson

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-140462

Published: 2020

Journal Articles

Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)

Blood (2020) 136 (Supplement 1): 19–22.

https://doi.org/10.1182/blood-2020-134676

Published: 2020

Journal Articles

Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL® Registry

Anthony Mato, MD, Chadi Nabhan, MD, Christopher Flowers, MD, Neil E. Kay, MD, Thomas J. Kipps, MD, PhD, David L. Grinblatt, MD, Nicole Lamanna, MD, Mark Kozloff, MD, Kristen Sullivan, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Jeff P. Sharman, MD

Blood (2015) 126 (23): 4483.

https://doi.org/10.1182/blood.V126.23.4483.4483

Published: 2015

Journal Articles

Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL® Cohort Study

Christopher Flowers, MD, Chadi Nabhan, MD, Neil E. Kay, MD, Anthony Mato, MD, Nicole Lamanna, MD, David L. Grinblatt, MD, Thomas J. Kipps, MD, PhD, Mark Kozloff, MD, Kristen Sullivan, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Jeff P. Sharman, MD

Blood (2015) 126 (23): 3284.

https://doi.org/10.1182/blood.V126.23.3284.3284

Published: 2015

Journal Articles

Autologous Stem Cell Transplantation in First Complete Remission May Not Extend Progression Free Survival in Patients with ALK-Negative Peripheral T Cell Lymphoma

Clinton Yam, MBBS, Daniel J. Landsburg, MD, Xinyi Lin, PhD, Anthony Mato, MD, Jakub Svoboda, MD, Alison Loren, MD MS, Noelle Frey, MD, Edward A. Stadtmauer, MD, David Porter, MD, Stephen J. Schuster, MD, Sunita Dwivedy Nasta, MD

Blood (2015) 126 (23): 3183.

https://doi.org/10.1182/blood.V126.23.3183.3183

Published: 2015

Journal Articles

Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations with Prognostic Significance in Chronic Lymphocytic Leukemia

Jie Wang, MD, Jennifer J.D. Morrissette, PhD, E. Paul Wileyto, PhD, Stephen J. Schuster, MD, Alexandra Vandegrift, BA, Allison Rago, BSN, Colleen Dorsey, BSN, David Porter, MD, Daniel J. Landsburg, MD, Prioty Islam, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, Alison Loren, MD MS, Scott Weber, BS, Edward A. Stadtmauer, MD, Anthony Mato, MD

Blood (2015) 126 (23): 2929.

https://doi.org/10.1182/blood.V126.23.2929.2929

Published: 2015

Journal Articles

Long Term Outcomes of Rituximab, Temozolamide, and High-Dose Methotrexate for Lymphoma Involving the Central Nervous System

Sarah Jordan Nagle, MD, Nirav N. Shah, MD, Alex Ganetsky, PharmD, BCOP, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Anthony Mato, MD, Stephen J. Schuster, MD, Donald Edward Tsai, MD PhD, Jakub Svoboda, MD

Blood (2015) 126 (23): 2701.

https://doi.org/10.1182/blood.V126.23.2701.2701

Published: 2015

Journal Articles

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma

Marco Ruella, MD, Saad S Kenderian, MD, Olga Shestova, PhD, Joseph A. Fraietta, PhD, Sohail Qayyum, MD, Qian Zhang, MD PhD, Marcela V. Maus, MDPhD, Xiaobin Liu, PhD, Selene Nunez-Cruz, PhD, Michael Klichinsky, PharmD, Omkar Uday Kawalekar, MS, BS, Michael C. Milone, MD PhD, Simon F. Lacey, PhD BSc, Anthony Mato, MD, Stephen J. Schuster, MD, Michael Kalos, PhD, Carl H. June, MD, Saar I Gill, MBBS, PhD, Mariusz A. Wasik, MD

Blood (2015) 126 (23): 704.

https://doi.org/10.1182/blood.V126.23.704.704

Published: 2015

Journal Articles

Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study

Blood (2015) 126 (23): 719.

https://doi.org/10.1182/blood.V126.23.719.719

Published: 2015

Journal Articles

Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL® Registry

Charles M. Farber, MD, Anthony Mato, MD, Chadi Nabhan, MD, Thomas J. Kipps, MD, PhD, Christopher Flowers, MD, Neil E. Kay, MD, Nicole Lamanna, MD, David L. Grinblatt, MD, Mark Kozloff, MD, Mark Weiss, MD, Kristen Sullivan, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Jeff P. Sharman, MD

Blood (2015) 126 (23): 5270.

https://doi.org/10.1182/blood.V126.23.5270.5270

Published: 2015

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Updated results from a Phase II study of minimal residual disease-guided venetoclax + obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia

Molecular and structural basis of pan-resistance to BTK targeting therapies via BTK A428D mutation

A Phase II multicenter study of minimal residual disease-guided, time-limited acalabrutinib + obinutuzumab for the initial treatment of chronic lymphocytic leukemia

Pre-Clinical Evaluation of AZD5492, a Novel CD8-Guided T Cell Engager, for B-Non Hodgkin Lymphoma Indications

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax in the Clinical Trial and Post-Marketing Settings

A Clinical Practice Comparison of Overall Survival, Time-to-Next-Treatment, and Time-to-Treatment-Discontinuation Among CLL/SLL Patients Receiving First-Line Ibrutinib with and without a Del(17p) Mutation

COVID-19 Impact on Lymphoma Patients' Clinical Outcomes - an Observational Cohort Study

LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study

The Prosid Study: Evaluating Efficacy and Safety of Intravenous Immunoglobulin (IVIG) 10% in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia- Study Design

Improving Physician-Patient Decision Making for Treatment of Chronic Lymphocytic Leukemia with BTK Inhibition

Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)

Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL® Registry

Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL® Cohort Study

Autologous Stem Cell Transplantation in First Complete Remission May Not Extend Progression Free Survival in Patients with ALK-Negative Peripheral T Cell Lymphoma

Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations with Prognostic Significance in Chronic Lymphocytic Leukemia

Long Term Outcomes of Rituximab, Temozolamide, and High-Dose Methotrexate for Lymphoma Involving the Central Nervous System

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma

Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study

Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL® Registry

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only